The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
An Indiana state official in charge of regulatory oversight of nursing homes and residential care facilities has been barred from taking a job at a private company that runs senior living communities over ethics concerns.
President-elect Donald Trump promised to drive down the cost of medicines, defying investors who saw a boon in his election last month and injecting himself again into a contentious economic debate.
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
Anthem Inc. fired back against U.S. claims that the health insurer’s planned $48 billion takeover of rival Cigna Corp. will undermine competition.
The $6.3 billion bill would let the Food and Drug Administration approve drugs and medical devices more quickly and bolster federal mental health programs.
President-elect Donald Trump on Tuesday said he’ll nominate Seema Verma, founder of Indianapolis-based SVC Inc. and architect of the Healthy Indiana Plan, as his pick for administrator of the Centers for Medicare and Medicaid Services.
Analysts are all over the map on how investors should react to the Indianapolis-based drugmaker’s news that a promising drug failed to help patients.
Investors pummeled Eli Lilly and Co.’s stock Wednesday on the news that its experimental drug for Alzheimer’s disease failed to help patients, but a chorus of pharmaceutical analysts say they weren’t shocked by the setback.
What happens to a laboratory glove after a doctor, nurse or lab worker snaps it off and throws it in the bin? Usually, it goes to a landfill, but Purdue and partners are working to change that.
Cornerstone Autism Center plans to hire about 30 employees in the next year in the 96-year-old Polk Building, which is undergoing a major rehab by its new owner.
Anthem Inc.’s proposed merger with Cigna Corp. would reduce health-care competition and raise costs for consumers, U.S. antitrust lawyers will argue Monday when the government goes to court to try to block the transaction.
John Lechleiter told local leaders Friday morning that while community engagement might not immediately impact the bottom line, it can be beneficial to a company’s ongoing mission.
Hospitals are under pressure to serve healthier fare. Patients, health groups and news organizations are turning up the fire.
For patients, the difference between getting an operation now or in January could amount to thousands of dollars out of pocket.
Fairbanks, an Indianapolis not-for-profit that focuses on treating alcohol and drug addiction, has changed its leadership again, just a year after bringing in a new executive from Ohio.
